secwatch.observer — SEC 8-K summary
======================================

Issuer:     Praxis Precision Medicines, Inc. (PRAX)
CIK:        0001689548
Form:       8-K
Filed at:   2026-06-29T20:40:34+00:00
Accession:  0001689548-26-000069
Event type: regulatory
Sentiment:  neutral
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA extends relutrigine PDUFA date by 3 months to Dec 27, 2026
--------------------------------------------------------------

- FDA extended relutrigine NDA review by 3 months due to additional sensitivity analyses submitted by Praxis.
- New PDUFA target action date is December 27, 2026 (was September 27, 2026).
- FDA deemed submission a major amendment; no new clinical studies, safety, or manufacturing concerns cited.
- Company remains confident in application and continues preparations for launch.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1689548/000168954826000069/0001689548-26-000069-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1689548/000168954826000069/prax-20260629.htm
  HTML page:      https://secwatch.observer/filing/0001689548-26-000069

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer